drugset / Trial / NCT07318103

Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention

NCT07318103

Phase 2 Recruiting 153 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase II clinical study of HRS-9057 injection in patients with heart failure-induced fluid retention

Timeline

Start
2025-12-31
Primary completion
2026-07
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-9057 Unknown

Indications

No indication recorded.